@article{APS10455,
author = {Jie Huang and Yang Liu and Jia-xin Chen and Xin-ya Lu and Wen-jia Zhu and Le Qin and Zi-xuan Xun and Qiu-yi Zheng and Er-min Li and Ning Sun and Chen Xu and Hai-yan Chen},
title = {Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy},
journal = {Acta Pharmacologica Sinica},
volume = {43},
number = {1},
year = {2021},
keywords = {},
abstract = {Harmine is a β-carboline alkaloid isolated from Banisteria caapi and Peganum harmala L with various pharmacological activities, including antioxidant, anti-inflammatory, antitumor, anti-depressant, and anti-leishmanial capabilities. Nevertheless, the pharmacological effect of harmine on cardiomyocytes and heart muscle has not been reported. Here we found a protective effect of harmine on cardiac hypertrophy in spontaneously hypertensive rats in vivo. Further, harmine could inhibit the phenotypes of norepinephrine-induced hypertrophy in human embryonic stem cell-derived cardiomyocytes in vitro. It reduced the enlarged cell surface area, reversed the increased calcium handling and contractility, and downregulated expression of hypertrophy-related genes in norepinephrine-induced hypertrophy of human cardiomyocytes derived from embryonic stem cells. We further showed that one of the potential underlying mechanism by which harmine alleviates cardiac hypertrophy relied on inhibition of NF-κB phosphorylation and the stimulated inflammatory cytokines in pathological ventricular remodeling. Our data suggest that harmine is a promising therapeutic agent for cardiac hypertrophy independent of blood pressure modulation and could be a promising addition of current medications for cardiac hypertrophy.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10455}
}